title: Pharmacological therapy used in the elimination of Helicobacter pylori infection: a review.
abstract: The optimal therapy for Helicobacter pylori (H. pylori) infection should combine a high cure rate and a short treatment duration with a favorable side-effect profile and should maintain a low cost. Several strategies have been proposed to increase the H. pylori eradication rate, including the extension of the treatment duration to 14 d, the use of a four-drug regimen (quadruple, sequential, and concomitant treatments), and the use of novel antibiotics, such as levofloxacin. However, triple therapy remains the most widely accepted first-line treatment regimen in Brazil and the United States and throughout Europe. Because this therapy is limited by resistance to clarithromycin, other therapeutic regimens have been investigated worldwide. This review describes the current literature involving studies directly comparing these different therapies and their efficacies.
authors.affiliation: Ariolana A dos Santos, Adriana A Carvalho, Department of Pharmacy, Federal University of Sergipe, Campus Lagarto, 49400-00 Lagarto, Sergipe, Brazil.
authors.forename: Ariolana A
authors.initials: AA
authors.lastname: Dos Santos
authors.affiliation: Ariolana A dos Santos, Adriana A Carvalho, Department of Pharmacy, Federal University of Sergipe, Campus Lagarto, 49400-00 Lagarto, Sergipe, Brazil.
authors.forename: Adriana A
authors.initials: AA
authors.lastname: Carvalho
mesh_terms: D000900:Anti-Bacterial Agents / Q000009:adverse effects / Q000627:therapeutic use*; D024881:Drug Resistance, Bacterial; D004359:Drug Therapy, Combination; D016481:Helicobacter Infections / Q000175:diagnosis / Q000188:drug therapy* / Q000382:microbiology; D016480:Helicobacter pylori / Q000187:drug effects* / Q000472:pathogenicity; D006801:Humans; D054328:Proton Pump Inhibitors / Q000009:adverse effects / Q000627:therapeutic use*; D016896:Treatment Outcome
chemical_list: D000900:Anti-Bacterial Agents; D054328:Proton Pump Inhibitors
keywords: Clarithromycin resistant; Helicobacter pylori; Peptic ulcers; Treatment; Triple therapy